Abstract
The aim of this work was to evaluate novel three-domain antibodies consisting of two domains specific for human tumor necrosis factor (hTNF), and of the third domain responsible for binding to myeloid cells. The additional hTNF-binding domain should serve to increase the biological activity of new antibodies. Capacity of these proteins to bind hTNF on the macrophage surface and to neutralize its biological activity in vitro was assessed.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
